Angiotensin II Receptor Blocker Drug to Boost the Potential of PD-1 Inhibitor Immunotherapy

Angiotensin II Receptor Blocker Drug to Boost the Potential of PD-1 Inhibitor Immunotherapy

Release Date: 23-Dec-2020



A novel study indicates that a class of drugs could patiently improve the response of the patients towards some of the anti-cancer immunotherapy drugs such as PD-L1 inhibitors. According to the researchers working on the clinical research study, Angiotensin II blockers was able to bind to the receptor of a protein which was observed to increase the level of the proteins such as VEGF and TGF beta, which are further linked with growth of the cancer cells and resistance to the immune system. It was stated by the researchers that the overlap found between angiotensin II and TGF beta was although important for playing a crucial role in the onset of the cancer and how it is able to escape the immune system.

 

A total of 597 patients were observed in the clinical research study and all were believed to be taking anti-PD-L1 drugs. Some of the patients that were enrolled in the clinical research study were taking angiotensin II receptor blockers (ARBs) for their heart problems. It was reported by the researchers that the patients who took ARBs showed better response rate to immunotherapy when compared with the patients who didn’t take any ARBs.

 

In addition to better response rate, the patients who received ARBs showed better objective response rate and overall reduction in the size of the tumor cells. Also, the patients who took ARBs are bound to love longer than the patients who haven’t received the drug. The cancer type which showed maximum results in the patients was bladder cancer. Although all the tests were preliminary but the clinical outcomes received through the test were encouraging for taking them further to next stage of clinical trial.

Need custom market research solution? We can help you with that too.